Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Oct;48(15):2328-38.
doi: 10.1016/j.ejca.2012.03.001. Epub 2012 Mar 27.

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis

Jiangbo Liu  1 , Qingyong Ma, Min Zhang, Xinshuai Wang, Dong Zhang, Wei Li, Fengfei Wang, Erxi Wu
Affiliations
Meta-Analysis

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis

Jiangbo Liu et al. Eur J Cancer. 2012 Oct.

Abstract

Background: The prognostic significance of p53 aberration in hepatocellular carcinoma (HCC) remains inconclusive. This systematic review and meta-analysis aimed to provide comprehensive evidence on the association of p53 alterations with recurrence-free survival (RFS) and overall survival (OS) in HCC patients.

Methods: Systematic literature searches were conducted until July 2010. Meta-analysis was performed to estimate prognostic effects of p53 alterations on patient outcomes in HCC. Sensitivity and subgroup analyses were also conducted in the meta-analysis.

Results: Thirty-seven studies (7 tumour p53 mutation, 23 tumour p53 expression and 7 serum anti-p53 antibodies) were included in the systematic review and meta-analysis. The average percentages of p53 mutation, p53 expression upregulation and anti-p53 antibody level elevation in HCC patients were 31.5%, 35.0% and 23.8%, respectively. Tumour p53 alterations were associated significantly with poor patient outcomes in HCC: the summary hazard ratio (HR) of mutant p53 versus wild type p53 phenotype was 2.58 [95% confidence interval (CI): 1.96-3.41] for OS and 3.19 [95% CI: 2.21-4.60] for RFS, respectively; and the summary HR of upregulated p53 expression versus low/undetectable p53 expression was 1.68 [95% CI: 1.49-1.90] for OS and 1.89 [95% CI: 1.34-2.66] for RFS, respectively. However, elevated serum anti-p53 antibody was only associated with poor OS in HCC group with a high proportion of (≥ 50%) of hepatitis C virus (HCV) infection [HR: 1.92; 95% CI: 1.30-2.85]. Moreover, sensitivity analyses showed that the results of meta-analyses were not altered.

Conclusion: HCC patients with p53 mutation and upregulated expression in tumour tissue have a shorter OS and RFS than patients with wild type p53 and low/undetectable p53 expression. However, the prognostic value of serum anti-p53 antibody is required to be further examined.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

The authors of this manuscript have no potential conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Flow chart of literature selection for the systematic review and meta-analysis.
Fig. 2
Fig. 2
Forest plot of comparison between p53 mutation and wild type p53 phenotype on OS and RFS in HCC patients. Hazard ratio and associated 95% confidence interval were calculated using the fixed-effects model. OS, overall survival; RFS, recurrence-free survival.
Fig. 3
Fig. 3
Forest plot of comparison between p53 upregulation and low/undetectable p53 expression on OS and RFS in HCC patients. Hazard ratio and associated 95% confidence interval were calculated using the fixed-effects model for studies with OS and the random-effects model for RFS. OS, overall survival; RFS, recurrence-free survival.
Fig. 4
Fig. 4
Forest plot of comparison between elevated and low/undetectable serum anti-p53 antibody on OS and RFS in HCC patients. Hazard ratio and associated 95% confidence interval were calculated using the fixed-effects model. OS, overall survival; RFS, recurrence-free survival.
See this image and copyright information in PMC

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. - PubMed
    1. Jemal A, Siegel RWE, Hao YP, Xu JQ, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. - PubMed
    1. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF., Jr International trends and patterns of primary liver cancer. Int J Cancer. 2001;94(2):290–96. - PubMed
    1. La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer. 2000;36(7):909–15. - PubMed
    1. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29(4):502–10. - PMC - PubMed

Publication types

MeSH terms